05/17/22 4:05 PMNasdaq : XAIR Beyond Air® Presents Positive Study Update from the At-Home LungFit® GO Pilot Study for Nontuberculous Mycobacterial Lung Disease at the American Thoracic Society International Conference 2022A total of 2,323 inhalations have been self-administered at home to date with no treatment related discontinuations reported and overall high treatment compliance All subjects have successfully titrated to receive the target 250 ppm NO regimen at home LungFit® GO is the first NO generator andRHEA-AIneutral
05/17/22 7:00 AMNasdaq : XAIR managementBeyond Cancer, Ltd. Appoints Susan Howell Jones, CPA as Chief Financial OfficerBeyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for theRHEA-AIneutral
05/16/22 7:05 AMNasdaq : XAIR earningsBeyond Air® Schedules Fiscal Year 2022 Financial Results Conference Call and WebcastBeyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients withRHEA-AIneutral
04/25/22 4:05 PMNasdaq : XAIR Beyond Air® Reports Positive Long-Term Safety Data for High Concentration Inhaled Nitric Oxide in Bronchiolitis at the Pediatric Academic Societies Meeting 2022Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections andRHEA-AIneutral
04/25/22 7:00 AMNasdaq : XAIR covid-19Beyond Air® Presents Positive Safety and Efficacy Data for Inhaled Nitric Oxide to Treat COVID-19 at ECCMID 2022Inhaled NO treatment in patients hospitalized with COVID-19 and other community-acquired viral pneumonia was well tolerated overall, and safe, with improved efficacy parameters as compared to standard supportive treatment Duration of oxygen support was significantly shorter for subjects treatedRHEA-AIneutral
04/18/22 7:00 AMNasdaq : XAIR conferencesBeyond Air® to Participate in Three Upcoming Medical ConferencesBeyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections andRHEA-AIneutral
04/11/22 7:00 AMNasdaq : XAIR clinical trialBeyond Cancer™ Announces New Preclinical Data Presented at American Association for Cancer Research (AACR) Showing Ultra-High Concentration Nitric Oxide Therapy Anti-Tumor EffectData suggests ultra-high concentration gaseous NO (gNO) induced both innate and adaptive immune cell populations, and a decline in immune suppressor cells, which are indicative of an anti-tumor immune response Supports the hypothesis for the observed rejection of secondary tumors in gNO-treatedRHEA-AIneutral
03/08/22 4:35 PMNasdaq : XAIR conferencesBeyond Cancer™ to Present Two Abstracts for Ultra-High Concentration Nitric Oxide Therapy at the 2022 AACR Annual MeetingBeyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developingRHEA-AIneutral
02/10/22 4:05 PMNasdaq : XAIR earningsBeyond Air® Reports Financial Results for the Third Quarter of Fiscal Year 2022LungFit ® PH premarket approval (PMA) submission under active review by U.S. FDA; approval and commercial launch anticipated in the first half of calendar year 2022 along with European CE Mark Raised $30 million for oncology affiliate Beyond Cancer™, Beyond Air maintained an 80% equity ownership;RHEA-AIpositive
02/08/22 8:00 AMNasdaq : XAIR conferencesBeyond Air® Announces Participation at Upcoming Investor Conferences in March 2022Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections andRHEA-AIneutral